Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma

Celgene’s Revlimid may have slipped in tandem with Roche’s Rituxan in previously untreated follicular lymphoma patients. But in the second-line setting, the drug has a win.